Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $180 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) with a maintained price target of $180.
April 10, 2024 | 1:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Jazz Pharmaceuticals with a maintained price target of $180.
The reiteration of an Overweight rating and the maintenance of a $180 price target by a reputable analyst suggests a positive outlook for Jazz Pharmaceuticals. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100